Abstract

Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory symptoms. Here we perform a comprehensive analysis of the plasma proteome of more than 1400 proteins in children with SARS-CoV-2. We hypothesize that the proteome would reflect heterogeneity in hyperinflammation and vascular injury, and further identify pathogenic mediators of disease. We show that protein signatures demonstrate overlap between MIS-C, and the inflammatory syndromes macrophage activation syndrome (MAS) and thrombotic microangiopathy (TMA). We demonstrate that PLA2G2A is an important marker of MIS-C that associates with TMA. We find that IFNγ responses are dysregulated in MIS-C patients, and that IFNγ levels delineate clinical heterogeneity.

Multi-inflammatory syndrome in children (MIS-C) can be associated with SARS-CoV-2 infection but can also be similar to other inflammatory syndromes. Here the authors characterise the plasma proteome phenotype in MIS-C and compare to other SARS-CoV-2 related syndromes and find disproportionately high IFN-γ responses in MIS-C patients.

Details

Title
Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction
Author
Diorio, Caroline 1 ; Shraim Rawan 2 ; Vella, Laura A 3 ; Giles, Josephine R 4 ; Baxter, Amy E 4   VIAFID ORCID Logo  ; Oldridge, Derek A 5 ; Canna, Scott W 6 ; Henrickson, Sarah E 7 ; McNerney, Kevin O 8 ; Balamuth Frances 9 ; Chakkapong, Burudpakdee 1 ; Lee, Jessica 1 ; Leng Tomas 8   VIAFID ORCID Logo  ; Farrel Alvin 2 ; Lambert, Michele P 10   VIAFID ORCID Logo  ; Sullivan, Kathleen E 11 ; John, Wherry E 4   VIAFID ORCID Logo  ; Teachey, David T 1   VIAFID ORCID Logo  ; Bassiri Hamid 12 ; Behrens, Edward M 6 

 University of Pennsylvania Perelman School of Medicine, Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Department of Biomedical and Health Informatics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Institute for Immunology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Institute for Immunology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Institute for Immunology, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Pathology and Laboratory Medicine, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Rheumatology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Division of Allergy and Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Division of Oncology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Pennsylvania Perelman School of Medicine, Division of Emergency Medicine, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
10  University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
11  University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Allergy and Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
12  University of Pennsylvania Perelman School of Medicine, Immune Dysregulation Frontier Program, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania Perelman School of Medicine, Division of Infectious Diseases, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2608621874
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.